Objective: Previous studies suggested that polymorphisms in the coding region of the preproghrelin were involved in the etiology of obesity and might modulate glucose-induced insulin secretion. We evaluated the association of a new variation, À604C4T, in the promoter region of the ghrelin gene, of Leu72Met (247C4A) and of Gln90Leu (265A4T), all haplotypetagging single nucleotide polymorphisms (SNPs), with measures of insulin sensitivity in 1420 adult individuals. Research methods: The three SNPs were genotyped using ABI PRISM 7900 HT Sequence Detection System. We used multiple linear regression analysis for quantitative traits and THESIAS software for haplotype analysis. Results: We observed a protective effect exerted by Met72 variant of Leu72Met SNP on insulin resistance parameters; a significant decreasing trend from Leu/Leu to Leu/Met and to Met/Met homozygous subjects in triglycerides, fasting insulin levels and HOMA-IR index (P ¼ 0.02, 0.01 and 0.003, respectively), and, consistently, an increase in ghrelin levels (P ¼ 0.003) was found. A significant decrease from CC to TC and to TT genotypes in insulin levels and HOMA-IR index was also detected (P ¼ 0.00l for both), but only in subjects homozygous for Leu72, where the protective effect of Met72 was not present. The haplotype analysis results supported the data obtained by the evaluation of each single SNP, showing the highest value of insulin levels and HOMA-IR index in the À604 T 247 C and lowest value in À604 C 247 A . Conclusion: Our observations suggest a protective role of the Met72 variant and of À604 T allele in modulating insulin resistance. These SNPs or an unknown functional variant in linkage disequilibrium could increase ghrelin levels and probably insulin sensitivity.
Introduction
Ghrelin (GHRL), the endogenous ligand of the growth hormone secretagogue receptor (GHSR) is a circulating 28-amino acid brain-gut peptide that is widely expressed in many tissues and primarily produced by the stomach. 1 The peptide stimulates growth hormone release and appetite. 2, 3 A previous study reported that the gastric hormone ghrelin 4 provides a peripheral signal to the brain that induces adiposity in rodents; 5 it also regulates the weight balance through the GHSR by activation of neuropeptide Y and agouti-related peptide containing neurons in the hypothalamus. 6, 7 Circulating ghrelin levels are inversely correlated with obesity, insulin resistance parameters and type 2 diabetes, more so it has been observed that insulin may be an important regulator of plasma ghrelin in different states of nutrition. [8] [9] [10] [11] Hence, mutations in the GHRL gene could influence the function of ghrelin hormone and might alter the energy balance.
It is well known that mRNAs and/or propeptides can code for several proteins with different activities. Apart from ghrelin, preproghrelin codes for a 22 amino-acid amidated peptide obestatin, which is the ligand of the previously orphan receptor GPR39, a member of the ghrelin receptor family. 12 Obestatin reduces food intake and slows bowel motility, but has no effect on growth hormone release. Previous studies suggested that polymorphisms in the coding region of the preproghrelin were involved in the etiology of obesity and might modulate glucose-induced insulin secretion; [13] [14] [15] [16] Met72 allele carriers of Leu72Met variant seem to be protected against fat accumulation and visceral metabolic disorders. It has been shown as an association of such variants with type 2 diabetes-related phenotypes. 15, 17 However, with regard to the association between polymorphisms in GHRL and obesity-related metabolic disorders, published reports are conflicting. [13] [14] [15] [16] [17] In view of these considerations, we evaluated the possible association of the three GHRL haplotype-tagging single nucleotide polymorphisms (SNPs) À604 C4T, Leu72Met and Gln90Leu, with obesity and metabolic abnormalities of the insulin resistance state in a large population of individuals. The first polymorphism is a variation located in the promoter region of GHRL gene; the Leu72Met (C247A) is located between the mature ghrelin and the obestatin peptide. 18 The functional consequences of this variant are unknown; although it does not change the sequence of the mature ghrelin, altered mRNA stability or changes in protein processing may modify ghrelin secretion and/or activity, as was described for the proinsulin. 19 The Gln90Leu (A265 T) SNP causes an amino-acid change in the obestatin peptide, the possible consequences of this change are unknown.
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Subjects and methods
Subjects
We studied 1420 unrelated Caucasian subjects (mean age 43.83 ± 14.93), including a group of normal-weight subjects n ¼ 500 (body mass index, BMI)p25 kg m À2 (range [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] kg m À2 ) randomly selected from a population of healthy individuals living in the same geographical area and a group of overweight/obese subjects n ¼ 920 BMI425 kg m À2 (range In all subjects BMI and blood pressure were measured as well as fasting glucose, insulin plasma levels and lipid profile (total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol and triglycerides). Furthermore, during the last year of recruitment, another aliquot of serum was collected, to measure ghrelin concentrations, from the last 300 overweight/obese consecutive subjects.
Exclusion criteria for overweight/obese subjects were: previous diagnosis of diabetes according to ADA criteria, 20 chronic liver diseases and any treatment known to interfere with insulin sensitivity and metabolic syndrome-related parameters. All subjects gave written informed consent to participate in the study. The study protocol was approved by the Ethical Committee of the University of Rome 'Sapienza'.
Methods
Cholesterol and triglycerides concentrations were determined in plasma by Technicon RA-1000 Autoanalyzer; HDL was measured after precipitation of ApoB-containing lipoproteins with photungstic acid/MgCl 2 . LDL-cholesterol was calculated with the Friedewald formula. 21 Glucose levels were calculated by the glucose oxidase method (Autoanalyzer, Beckman Coulter, Fullerton, CA, USA). Plasma insulin was measured in frozen samples by radioimmunoassay (Adaltis insulin kit, Bologna, Italy), according to the manufacturer's instruction, with a limit of detection of o2.0 mU ml
À1
. 22 Insulin resistance status was estimated according to Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) following the formula previously described: 23 fasting insulin (mcU ml
Human plasma ghrelin was determined in duplicate in the last 300 overweight/obese consecutive subjects by RIA kits (ghrelin human RIA kit catalog no. RK-031-30, Phoenix Pharmaceuticals, Belmont, CA, USA). Phoenix's ghrelin human RIA kit detects full-length, desoctanoyl human ghrelin, including Ser3-octanoyl and Ser3-des-octanoyl ghrelins. The plasma samples were collected under fasting conditions.
Genotyping polymorphisms
The À604 C4T SNP in the promoter region of ghrelin gene has been identified by our group (paper submitted) by direct sequencing using seven sets of primers using the ABI Prism 3700 DNA Analyzer in the promoter region and recently by U Mager et al. 24 The À604 C4T (rs27647), Leu72Met (rs696217) and Gln90Leu (rs4684677) SNPs were analyzed using the flurogenic 5 0 nuclease assay application of the ABI PRISM 7900 HT Sequence Detection System (ABI, foster City, CA, USA).
Statistical analysis
Statistical analysis was performed using SPSS statistical software, version 13 (SPSS, Chicago, IL, USA). Genotypic and allelic distributions were compared using the Pearson's w 2 -test. The effect of the polymorphisms on quantitative variables was investigated using multiple linear regression analysis. We added in the analysis BMI, gender and age as covariates to adjust the crude effect of the polymorphisms. Data for insulin, triglycerides, ghrelin and HOMA-IR, were log 10 transformed to normalize their distribution.
The haplotype frequencies and the Linkage Disequilibrium (LD) matrix based on the D 0 parameter, were estimated using 
Results
The genotype distributions of À604 C4T, Leu72Met (247 C4A) and Gln90Leu (265 A4T) polymorphisms were in Hardy-Weinberg equilibrium (0.22, 0.9 and 0.13, respectively). The allele frequencies of the three variants were: 0.37 for the T allele of the À604 C4T, 0.09 for Met allele of the Leu72Met and 0.05 for Leu allele of the Gln90Leu (Table 1) . Analysis of Leu72Met SNP association with phenotypic traits, seems to display a co-dominant genetic model. We observed a significant decreasing trend from Leu/Leu homozygous, to Leu/Met heterozygous and to Met/Met homozygous for triglycerides, fasting insulin levels and HOMA-IR index (P ¼ 0.02, 0.01 and 0.001, respectively) ( Table 2) .
Consistently with these findings, a significant increasing trend was observed in ghrelin levels for the above-mentioned genotypes (P ¼ 0.003) ( Table 2 ). The À604 C4T SNP was analyzed in the whole cohort determining a trend of decrease from CC to TC and to TT for insulin levels and HOMA-IR index; however, the data was not statistically significant (P ¼ 0.08 for both) (data no shown). When the analysis for À604 C4T polymorphism was performed in subjects homozygous for Leu72, we noted a significant decreasing trend in insulin levels and HOMA-IR index (P ¼ 0.001 for both) (Table 3) ; moreover, an increasing trend was observed in ghrelin levels but it was not statistically significant (Table 3) . We confirmed that the 300 subjects who received ghrelin measurements, showed no significant differences to the whole population for important covariates (Table 4) .
There were no significant associations between Gln90Leu polymorphism and the investigated variables (data no shown). No significant association was found between BMI and the three genetic variants.
A strong LD was observed between the three polymorphisms (À604 C4T is in LD with either 247 C4A and 265 A4T, D 0 ¼ 0.87 and D 0 ¼ 0.93, respectively; the 247 C4A is in LD with 265A4T, D 0 ¼ 1) Table 1 . The haplotype analysis was performed only on À604 C4T and 247 C4A SNPs since the low frequency of 265 T allele.
All different haplotypes were estimated but only the ones with a frequency higher than 5% are shown in Table 5 (Table 5) . No significant association was found between haplotypes and ghrelin levels. b Performed in 300 overweight/obese subjects.
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Discussion
In the present study we evaluated the relationship of the following genetic variants of the ghrelin/obestatin gene: À604 C4T, Leu72Met C4A and Gln90Leu A4T, with measures of insulin resistance in a large cohort of subjects. We observed a significant association of the Leu72Met SNP and, for the first time, of the À604 C4T polymorphism (only in subjects homozygous for Leu72), with insulin resistance parameters. Met72Met homozygote subjects showed the highest ghrelin concentrations combined with the highest insulin sensitivity; we used fasting plasma ghrelin which have been previously shown to correlate with the 24 h integrated area under the curve values. 9 In order to enhance the validity of our results about ghrelin levels we underlined that the 300 subjects who received ghrelin measurements were similar from the rest of the whole population for important covariates. The protective effect of the À604 C4T variant was particularly evident in subjects homozygous for Leu72 allele, where the protective effect of Met72 was not evident. We could hypothesize that variants in the promoter region of ghrelin gene could regulate the gene transcription, although the factors regulating ghrelin production have not been clarified so far.
Although the Leu72Met and Gln90Leu SNPs were in complete LD, we did not observe any significant association Table 3 Clinical and biochemical parameters according to À604C4T SNP performed in Leu72 homozygous subjects Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; SBP, systolic blood pressure.
a P for trend; P-values were adjusted for age, BMI and gender.
b Performed in 300 overweight/obese subjects. Consistently with our results, a previous study indicated a protective role of Met72 variant on metabolic comorbidities and a trend toward an association with higher ghrelin concentration. 13 Poykko et al. 26 did not observe a significant difference in mean ghrelin values between Leu72Leu homozygotes and the Met72 carriers in subjects with hypertension, probably due to the limited number of Met72 homozygous subjects (n ¼ 8); however, also in this case, a clear trend toward an association was observed (Po0.09). The low frequency of the Met72Met genotype in the general population clearly represents a limit to demonstrate the association with increased ghrelin plasma levels. Inversely, a recent study did not find association between the two polymorphisms (À604 C4T and Leu72Met) and measures of insulin resistance probably due to the different study design that was performed in the IGT subjects. 24 Ghrelin acutely inhibits insulin secretion in humans after injection, 27 however other studies have observed stimulatory effects. 28 Despite the controversial data about the direct effect of ghrelin on insulin secretion, the independent association between low ghrelin level and fasting insulin concentrations, insulin resistance and type 2 diabetes has been clearly demonstrated 26 supporting the view that low ghrelin level could have a contributing role in the development of insulin resistance. Our findings are in accordance with these results showing that ghrelin levels are positively associated with insulin sensitivity. We could hypothesize that the 604 C 247 A haplotype or an unknown nearby functional variant in LD, could increase ghrelin levels and consequently insulin sensitivity. Thus, the influence of the ghrelin SNPs on insulin resistance may be, at least in part, explained by their correlation with ghrelin plasma levels. The association of the same ghrelin polymorphisms evaluated in the present study with obesity and obesityrelated phenotypes has been previously evaluated in different populations, however the results of the studies are sometimes conflicting. [13] [14] [15] [16] Inconsistency between findings could be real and due to genetic heterogeneity or differences between populations in environmental factors that influence the phenotypic expression of the gene variant. More detailed characterization, as well as functional studies of these variants will be necessary to further define the role of ghrelin polymorphisms in defining risk for metabolic abnormalities of obesity and to delineate the molecular and physiological mechanisms of their effects.
In conclusion our observations suggest that À604 C4T and Leu72Met ghrelin gene polymorphisms modulate insulin sensitivity. Our findings lead to the hypothesis of a prominent role of the Met72 variant respect to that of the -604 T variant in modulating insulin resistance and ghrelin levels, considering that the effect of the promoter SNP is underlined only in subjects not carrying the Met72 variant.
